SEC Form 4 · accession 0001209191-18-057820
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Aliski
Director
Period of report
Nov 8, 2018
Accepted (ET)
Nov 8, 2018 · 6:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 8, 2018 | S | 6,000 | $55.67 | D | 96,350 | I | By trust |
| Common Stock | holding | — | — | — | 72,610 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported on this Form 4 was effected pursuant to a trading plan adopted by the Reporting Person's trust pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust.